• Over 30 years in Medicine. Pediatric Hematologist-Oncologist: Technion, Harvard Medical School, Oxford University, UCLA, Cedars Sinai

• World renowned expert in Molecular Genetics. Biotech company sold to Pfizer.

• Over 25 years of experience in public equity markets

 

Dr. Nathan Fischel is the founder of DAFNA Capital Management and has been its CEO since inception in January 1999.

 

Dr. Fischel was raised in Germany, went to boarding school in France, attended Medical School at the Technion School of Medicine in Israel and served his internship year at Hadassah Hospital in Jerusalem. He completed his residency and fellowship in Pediatrics and Pediatric Hematology and Oncology at the Children’s Hospital and the Dana-Farber Cancer Institute, Harvard Medical School in Boston, and his postgraduate research training in Molecular Genetics at Oxford University in England.

 

Dr. Fischel was Professor of Pediatrics at UCLA School of Medicine, and Director of Molecular Hematology and attending physician at Cedars-Sinai Medical Center. He is currently Professor Emeritus at UCLA. He has published over 120 peer-reviewed scientific and medical manuscripts and book chapters, has been the principal investigator of multiple National Institutes of Health (“NIH”) funded research grants, has served repeatedly on internal and external review panels at the NIH, and in 2005 was appointed by the U.S. Secretary of Health and Human Services to serve for four years on the Advisory Council of one of the NIH’s institutes.

 

In 1993, Dr. Fischel co-founded a venture capital-backed genomics biotechnology company, and served as the Chief Scientific Officer and as a member of the Board of Directors; the company was later acquired by Warner-Lambert (Pfizer).

​

Dr. Fischel currently serves as a member of the Board of Directors of Stereotaxis Inc., a publicly traded medical technology company.

 

Click on the following to access a list of Dr. Fischel's Grants, Lectures, Scientific Publications, Book Chapters / Reviews / Editorials, and Patents.